vs
Side-by-side financial comparison of Envela Corp (ELA) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $80.5M, roughly 1.1× Envela Corp). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 7.4%, a 15.3% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 66.6%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-3.7M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 42.1%).
Envela Corporation is a U.S.-based company that provides recommerce services aimed at extending product lifecycles and reducing resource consumption. The company operates through two primary segments: consumer and commercial.
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
ELA vs FDMT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $80.5M | $85.1M |
| Net Profit | $6.0M | $19.4M |
| Gross Margin | 20.5% | — |
| Operating Margin | 9.4% | 17.3% |
| Net Margin | 7.4% | 22.8% |
| Revenue YoY | 66.6% | 8508900.0% |
| Net Profit YoY | 274.6% | 139.1% |
| EPS (diluted) | $0.22 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $80.5M | $85.1M | ||
| Q3 25 | $57.4M | $90.0K | ||
| Q2 25 | $54.9M | $15.0K | ||
| Q1 25 | $48.3M | $14.0K | ||
| Q4 24 | $48.3M | $1.0K | ||
| Q3 24 | $46.9M | $3.0K | ||
| Q2 24 | $45.3M | $5.0K | ||
| Q1 24 | $39.9M | $28.0K |
| Q4 25 | $6.0M | $19.4M | ||
| Q3 25 | $3.4M | $-56.9M | ||
| Q2 25 | $2.8M | $-54.7M | ||
| Q1 25 | $2.5M | $-48.0M | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $1.7M | $-43.8M | ||
| Q2 24 | $1.6M | $-35.0M | ||
| Q1 24 | $1.9M | $-32.4M |
| Q4 25 | 20.5% | — | ||
| Q3 25 | 22.8% | — | ||
| Q2 25 | 22.6% | — | ||
| Q1 25 | 24.8% | — | ||
| Q4 24 | 23.1% | — | ||
| Q3 24 | 24.4% | — | ||
| Q2 24 | 25.1% | — | ||
| Q1 24 | 25.9% | — |
| Q4 25 | 9.4% | 17.3% | ||
| Q3 25 | 7.3% | -67983.3% | ||
| Q2 25 | 5.9% | -396373.3% | ||
| Q1 25 | 6.5% | -383007.1% | ||
| Q4 24 | 3.9% | — | ||
| Q3 24 | 4.3% | -1704400.0% | ||
| Q2 24 | 4.2% | -849120.0% | ||
| Q1 24 | 5.9% | -136200.0% |
| Q4 25 | 7.4% | 22.8% | ||
| Q3 25 | 5.8% | -63195.6% | ||
| Q2 25 | 5.0% | -364386.7% | ||
| Q1 25 | 5.2% | -342657.1% | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 3.6% | -1461433.3% | ||
| Q2 24 | 3.5% | -699060.0% | ||
| Q1 24 | 4.8% | -115717.9% |
| Q4 25 | $0.22 | $0.43 | ||
| Q3 25 | $0.13 | $-1.01 | ||
| Q2 25 | $0.11 | $-0.98 | ||
| Q1 25 | $0.10 | $-0.86 | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $0.06 | $-0.79 | ||
| Q2 24 | $0.06 | $-0.63 | ||
| Q1 24 | $0.07 | $-0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $402.7M |
| Total DebtLower is stronger | $9.9M | — |
| Stockholders' EquityBook value | $67.1M | $505.7M |
| Total Assets | $96.0M | $566.7M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $402.7M | ||
| Q3 25 | — | $305.1M | ||
| Q2 25 | — | $293.2M | ||
| Q1 25 | — | $321.4M | ||
| Q4 24 | — | $424.9M | ||
| Q3 24 | — | $501.9M | ||
| Q2 24 | — | $541.9M | ||
| Q1 24 | $19.8M | $525.9M |
| Q4 25 | $9.9M | — | ||
| Q3 25 | $12.5M | — | ||
| Q2 25 | $13.0M | — | ||
| Q1 25 | $13.2M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $13.8M | — | ||
| Q2 24 | $14.3M | — | ||
| Q1 24 | $14.6M | — |
| Q4 25 | $67.1M | $505.7M | ||
| Q3 25 | $61.1M | $369.0M | ||
| Q2 25 | $57.8M | $420.9M | ||
| Q1 25 | $55.1M | $469.7M | ||
| Q4 24 | $52.7M | $510.6M | ||
| Q3 24 | $51.1M | $552.9M | ||
| Q2 24 | $50.2M | $588.3M | ||
| Q1 24 | $49.3M | $600.6M |
| Q4 25 | $96.0M | $566.7M | ||
| Q3 25 | $90.9M | $424.0M | ||
| Q2 25 | $82.7M | $473.6M | ||
| Q1 25 | $79.7M | $515.7M | ||
| Q4 24 | $77.9M | $560.4M | ||
| Q3 24 | $77.4M | $604.0M | ||
| Q2 24 | $73.8M | $620.1M | ||
| Q1 24 | $74.7M | $629.9M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.26× | — | ||
| Q3 24 | 0.27× | — | ||
| Q2 24 | 0.29× | — | ||
| Q1 24 | 0.30× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.5M | $28.6M |
| Free Cash FlowOCF − Capex | $-3.7M | $28.5M |
| FCF MarginFCF / Revenue | -4.6% | 33.5% |
| Capex IntensityCapex / Revenue | 0.2% | 0.1% |
| Cash ConversionOCF / Net Profit | -0.59× | 1.47× |
| TTM Free Cash FlowTrailing 4 quarters | $1.4M | $-109.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.5M | $28.6M | ||
| Q3 25 | $2.4M | $-46.5M | ||
| Q2 25 | $2.6M | $-43.4M | ||
| Q1 25 | $1.1M | $-47.8M | ||
| Q4 24 | $3.7M | $-134.6M | ||
| Q3 24 | $3.4M | $-29.4M | ||
| Q2 24 | $-789.5K | $-30.2M | ||
| Q1 24 | $3.8M | $-29.1M |
| Q4 25 | $-3.7M | $28.5M | ||
| Q3 25 | $2.2M | $-46.6M | ||
| Q2 25 | $2.1M | $-43.4M | ||
| Q1 25 | $746.6K | $-48.4M | ||
| Q4 24 | $3.2M | $-138.4M | ||
| Q3 24 | $1.5M | $-31.2M | ||
| Q2 24 | $-1.3M | $-30.6M | ||
| Q1 24 | $3.3M | $-29.8M |
| Q4 25 | -4.6% | 33.5% | ||
| Q3 25 | 3.8% | -51765.6% | ||
| Q2 25 | 3.9% | -289620.0% | ||
| Q1 25 | 1.5% | -345635.7% | ||
| Q4 24 | 6.7% | -13837100.0% | ||
| Q3 24 | 3.1% | -1038966.7% | ||
| Q2 24 | -2.9% | -611840.0% | ||
| Q1 24 | 8.4% | -106421.4% |
| Q4 25 | 0.2% | 0.1% | ||
| Q3 25 | 0.4% | 101.1% | ||
| Q2 25 | 0.8% | 440.0% | ||
| Q1 25 | 0.8% | 4507.1% | ||
| Q4 24 | 1.0% | 378600.0% | ||
| Q3 24 | 4.2% | 59266.7% | ||
| Q2 24 | 1.1% | 6980.0% | ||
| Q1 24 | 1.1% | 2535.7% |
| Q4 25 | -0.59× | 1.47× | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.94× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 2.34× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | -0.50× | — | ||
| Q1 24 | 1.99× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELA
| Consumer Segment | $67.7M | 84% |
| Commercial Segment | $12.8M | 16% |
FDMT
Segment breakdown not available.
